The highly polymorphic cyclophilin A-binding loop in HIV-1 capsid modulates viral resistance to MxB by Zhenlong Liu et al.
Liu et al. Retrovirology  (2015) 12:1 
DOI 10.1186/s12977-014-0129-1SHORT REPORT Open AccessThe highly polymorphic cyclophilin A-binding
loop in HIV-1 capsid modulates viral resistance
to MxB
Zhenlong Liu1,6, Qinghua Pan1, Zhibin Liang1,2, Wentao Qiao2, Shan Cen3 and Chen Liang1,4,5*Abstract
Background: The human myxovirus-resistance protein B (MxB, also called Mx2) was recently reported to inhibit
HIV-1 infection by impeding the nuclear import and integration of viral DNA. However, it is currently unknown
whether there exist MxB-resistant HIV-1 strains in the infected individuals. Answer to this question should address
whether MxB exerts an inhibitory pressure on HIV-1 in vivo and whether HIV-1 has evolved to evade MxB inhibition.
Findings: We have examined ten transmitted founder (T/F) HIV-1 strains for their sensitivity to MxB inhibition by
infecting CD4+ T cell lines SupT1 and PM1 that were stably transduced to express MxB. Two T/F stains, CH040.c
and RHPA.c, were found resistant and this resistance phenotype was mapped to the amino acid positions 87 and
208 in viral capsid. The H87Q mutation is located in the cyclophilin A (CypA) binding loop and has a prevalence of
21% in HIV-1 sequences registered in HIV database. This finding prompted us to test other frequent amino acid
variants in the CypA-binding region and the results revealed MxB-resistant mutations at amino acid positions 86, 87,
88 and 92 in capsid. All these mutations diminished the interaction of HIV-1 capsid with CypA.
Conclusions: Our results demonstrate the existence of MxB-resistant T/F HIV-1 strains. The high prevalence of
MxB-resistant mutations in the CypA-binding loop indicates the significant selective pressure of MxB on HIV-1
replication in vivo especially given that this viral resistance mechanism operates at expense of losing CypA.
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Host restriction factors are important components of the
antiviral defense. HIV research has led to the discovery of
multiple restriction factors that not only inhibit HIV but
also a wide range of other viruses. Examples of these
restriction factors include APOBEC3G [1], Trim5α [2],
tetherin [3,4], and SAMHD1 [5,6] (reviewed in [7]). A re-
cent addition to this important family of proteins is human
myxovirus-resistance protein B (MxB, also called Mx2).
Despite the well-known antiviral property of MxA [8], no
virus was known to be inhibited by MxB until 2011 when
two screen studies showed that vesicular stomatitis virus
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unless otherwise stated.could be restricted by MxB [9,10]. The anti-HIV-1 activity
of MxB was further established by three independent stud-
ies which reported that MxB impedes HIV-1 DNA nuclear
import and/or integration by targeting viral capsid [11-13].
A number of mutations in viral capsid were shown to ren-
der HIV-1 resistant to MxB, including N57S, G89V, P90A,
N74D and others [12-15]. Furthermore, we identified in
the escape viruses a capsid mutation A88T that overcomes
MxB inhibition [11]. These results suggested that HIV-1
was able to escape MxB restriction by mutating its capsid
sequence. However, the aforementioned capsid mutations
are absent in the HIV sequence database likely because
they all cause severe defects in virus infectivity. We specu-
late that, if MxB does exert a strong inhibitory pressure on
HIV-1 infection in vivo, then there should exist MxB-
resistant HIV-1 strains.
To explore this possibility, we measured the effect of
MxB on ten transmitted founder (T/F) HIV-1 strains.
The T/F viruses were first produced by transfectings is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Inhibition of transmitted/founder (T/F) HIV-1 strains by MxB. (A) Ten T/F viruses were used to infect SupT1 cells that express MxB
with doxycycline induction. The MxB protein has a C-terminal FLAG tag as described previously [11]. Levels of newly produced HIV-1 were determined
by infecting the TZM-bl indicator cells. Folds of inhibition by MxB were calculated by dividing the amounts of HIV-1 produced from MxB-expressing
SupT1 cells with virus amounts produced by control SupT1 cells. Results shown are the average of three independent experiments. The T/F viral DNA
clones were obtained from the NIH AIDS Reagent Program [16,17]. (B) PM1 cells were stably transduced to express MxB under doxycyline induction,
and were infected with the above ten T/F HIV-1 strains. MxB inhibition was determined as described above. (C) Levels of exogenous MxB-FLAG in the
above SupT1 and PM1 cell lines, as determined by Western blotting. Tubulin was probed as the internal control. (D) Infectivity of the T/F HIV-1. The T/F
viruses were generated by transfecting the HEK293T cells. Viruses of the same levels of reverse transcriptase (RT) activity were used to infect the TZM-bl
indicator cells. The averages of three independent infections are shown. (E) Alignment of HIV-1NL4–3 capsid sequence with those of the two T/F viruses
CH040.c and RHPA.c. Red arrows indicate the three amino acid positions that are occupied by the same amino acids in CH040.c and RHPA.c but by
different amino acids in NL4-3. (F) Effects of mutations H87Q, H120N and G208A on the infectivity of HIV-1NL4–3. Virus infectivity was determined by
infecting the TZM-bl cells. Averages of three independent infections are shown. (G) Mutations H87Q and G208A render HIV-1NL4–3 resistant to MxB. The
mutants were tested in MxB-expressing SupT1 cells for their sensitivity to MxB inhibition.
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amounts were then determined by measuring viral reverse
transcriptase (RT) activity. Viruses of equal values of RT
activity were used to infect a SupT1 cell line that was sta-
bly transduced to express MxB under doxycycline induc-
tion [11]. Levels of viruses produced by these SupT1 cells
were determined by infecting the TZM-bl indicator cells
as previously described [11]. Consistent with what our
group and others reported [11-13], MxB inhibited theFigure 2 Polymorphisms in the CypA-binding loop of the viral capsid
the major polymorphisms in the CypA-binding loop of HIV-1 capsid. The p
sequences (5372 entries) that are available at HIV database (http://www.hiv
in the context of capsid structure (adapted from PDB ID 3P05) [19,20]. The
HIV-1NL4–3 strain. (B) Each of the nine major polymorphic amino acids was
were transfected into HEK293T cells to produce progeny virus particles. Viru
equal RT levels were used to infect the TZM-bl indicator cells. Results are su
at 1. (C) Wild type NL4-3 and its mutants were used to infect MxB-expressi
in Figure 1A. (D) Incorporation of CypA into the wild type and mutated HI
the culture supernatants were harvested by ultracentrifugation through a s
by HIV-1 p24 ELISA. Virus particles of the same p24 quantities were examin
HEK293T cells were also subject to Western blotting to assess levels of endHIV-1NL4–3 virus (a subtype B HIV-1 strain) by 8 to 10
fold (Figure 1A). The ten T/F viruses were inhibited to
different degrees, with two strains CH040.c and RHPA.c
exhibiting strong resistance to MxB (Figure 1A). We re-
peated this experiment in another CD4+ T cell line called
PM1. Overall, the T/F viruses were less restricted by MxB
in PM1 cells than in SupT1 cells (Figure 1B), which is
likely attributed to the relatively lower expression levels of
the exogenous MxB in PM1 cells (Figure 1C). Importantly,modulate HIV-1 susceptibility to MxB inhibition. (A) Illustration of
revalence of each variant was calculated on the basis of the capsid
.lanl.gov/content/index). The position of CypA-binding loop is shown
capsid sequence from amino acid positions 85 to 96 is from the
inserted into HIV-1NL4–3. The wild type NL4-3 and mutated viral DNA
s amounts were determined by measuring viral RT activity. Viruses of
mmarized in the bar graph with the infectivity of wild type NL4-3 set
ng SupT1 cells. Folds of inhibition by MxB were calculated as described
V-1NL4–3. Viral DNA was transfected into HEK293T cells. Virus particles in
ucrose gradient as described in [21]. Virus amounts were determined
ed in Western blotting for the presence of CypA. Lysates of transfected
ogenous CypA and viral Gag/p24 expression.
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in PM1 cells (Figure 1B). The infectivity of the ten T/F
viruses was also measured by infecting the TZM-bl indica-
tor cells (Figure 1D), which showed a wide range of
differences between the viruses. It is worth noting that the
MxB-resistant strains CH040.c and RHPA.c differed in
their infectivity by more than 30 fold. This suggests that
the resistance of both viruses to MxB is independent of
their infectivity levels.Figure 3 Association of wild type and mutated HIV-1NL4–3 capsid with
and A92P were used to infect MxB-expressing SupT1 cells or control SupT1
harvested, suspended in a hypotonic buffer containing 10 mM Tris–HCl (pH
Dounce homogenizer. After clearing cell debris by centrifugation at 3,000 r
M2 agarose (Sigma) for 4 hours at 4°C. After extensive washing, the bound
associated HIV-1 p24 were determined by ELISA. (A) Levels of MxB-FLAG, w
cells as determined by Western blotting. Amounts of wild type and mutate
bar graph. (B) Levels of wild type and mutated p24 that were associated w
blotting. For each virus, the amounts of viral p24 eluted from the M2 agar
the corresponding cell lysates. Levels of MxB-associated p24 were determ
MxB-expressing cells with those of M2 agarose-associated p24 from the c
infection experiments. (C) Levels of viral p24 in NL4-3 infected SupT1 cells
association with MxB. Detailed legend refers to (B).Given the role of the viral capsid in countering MxB
restriction [11-14], we aligned the capsid sequences of
CH040.c and RHPA.c with that of NL4-3. Three amino
acid positions in the capsid of both CH040.c and RHPA.
c differ from those in NL4-3 capsid (Figure 1E). These
are H87, H120 and G208 in NL4-3; Q87, N120 and
A208 in CH040.c and RHPA.c. We next inserted Q87,
N120 and A208 into NL4-3 capsid and generated muta-
tions H87Q, H120N and G208A in order to determineMxB. Wild type NL4-3 or its mutants V86A, V86Q, H87P, H87Q, A88V
cells without MxB expression. At 16 hours after infection, cells were
8.0), 10 mM KCl and 1 mM EDTA, and lysed with 15 strokes in a 7 ml
pm for 5 min at 4°C, cell lysates were incubated with the anti-FLAG
MxB was eluted with 3xFLAG peptide (Sigma) and the amounts of
ild type and the mutated HIV-1 p24/capsid in the infected SupT1
d p24 were also quantified by ELISA and results are shown in the
ith MxB. Levels of the eluted MxB-FLAG were assessed by Western
ose were determined by ELISA, then calibrated by p24 amounts in
ined by dividing the values of M2 agarose-associated p24 from
ontrol cells. Results shown are the average of three independent
under treatment of CSA (5 μM). (D) Effect of CSA treatment on p24
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None of these three mutations markedly affected the
infectivity of NL4-3 (Figure 1F). When these NL4-3 mu-
tants were tested in MxB-expressing SupT1 cells, H87Q
and G208A, but not H120N, were refractory to MxB
inhibition (Figure 1G).
H87 is located in the cyclophilin A (CypA)-binding loop
of HIV-1 capsid (Figure 2A) [18]. Q87 represents a major
variant at this position of capsid in the circulating HIV-1
strains, with 21% representation in the HIV database
(Figure 2A) (http://www.hiv.lanl.gov/content/index). This
prompted us to test the resistance of other major amino
acid variants in the CypA-binding loop, including V86A
(4.2%), V86Q (1.0%), H87P (1.1%), A88V (0.1%), I91V
(26.9%), A92P (27.4%), M96I (14%) and M96L (6.2%)
(Figure 2A). We inserted each of these eight capsid
variants into NL4-3. Except for A88V that reduced virus
infectivity by 4-fold, the other mutations were well toler-
ated by HIV-1NL-3 (Figure 2B). We then used these viruses
to infect MxB-expressing SupT1 cells and observed that
although the I91V, M96I and M96L mutants were as
sensitive to MxB inhibition as the wild type NL4-3
(Figure 2C), the mutants V86A, V86Q, H87P, H87Q,
A88V and A92P were all resistant to MxB (Figure 2C).
Therefore, at least six naturally existing amino acid vari-
ants at four positions in the CypA-binding loop render
resistance to MxB.
We have previously shown that either knockdown of
CypA or cyclosporine A (CSA) treatment to block CypA
rescued HIV-1 infection of MxB-expressing SupT1 cells
[11]. We therefore asked whether the above capsid vari-
ants in the CypA-binding loop modulated HIV-1 suscep-
tibility to MxB by altering the binding of CypA to the
viral capsid. To answer this question, we transfected the
wild type and mutated HIV-1NL4–3 DNA into HEK293T
cells and purified HIV-1 particles by ultracentrifugation
through a sucrose gradient [21]. The presence of CypA
in HIV-1 particles was examined by Western blotting
and the results showed that the wild type NL4-3 and
MxB-sensitive mutants I91V, M96I and M96L packaged
substantial amounts of CypA as opposed to the MxB-
resistant mutants V86A, V86Q, H87P, H87Q, A88V
and A92P that packaged little or no CypA (Figure 2D).
This data suggests that some HIV-1 strains have evolved
to escape MxB inhibition at the expense of losing viral
capsid binding to CypA.
Recent studies reported the association of MxB with
in vitro assembled HIV-1 capsid [22-24]. Therefore, in
addition to modulating the interaction of CypA with
HIV-1 capsid, the V86A, V86Q, H87P, H87Q, A88V and
A92P mutations may also affect the binding of MxB to
the viral capsid. To test this possibility, we infected
MxB-expressing SupT1 cells or the control SupT1 cells
with wild type HIV-1, or the above six MxB-resistantmutants. The MxB protein was then immunoprecipi-
tated, and the amount of MxB-associated HIV-1 p24/
capsid was determined by ELISA. The results revealed
that MxB was associated with HIV-1 capsid in the
infected SupT1 cells, albeit that both the wild type and
mutated viral capsids were associated with MxB to simi-
lar degrees (Figure 3A and B). In addition, treatment
with CSA did not diminish this interaction (Figure 3C
and D). This observation corroborates prior results
showing that neither mutations G89V and P90A in the
CypA-binding loop nor CSA treatment altered the asso-
ciation of MxB with the in vitro assembled HIV-1 capsid
complex [23,24].
In conclusion, we have identified two T/F HIV-1
strains that are resistant to MxB restriction in SupT1
and PM1 cells, and further mapped the resistant muta-
tions to viral capsid. Our data also revealed the high
prevalence of MxB-resistant mutations in the CypA-
binding loop of the viral capsid. Since these MxB-
resistant mutations diminish the association of viral
capsid with CypA which acts as a host dependency
factor for HIV-1, there is a cost for the virus to adopt
this MxB-resistant pathway, which helps to explain why
these MxB-resistant mutations have not prevailed the
circulating HIV-1 strains. Together with the recent find-
ing that the P207S, G208R and T210K mutations confer
resistance to MxB [14], our data on the G208A mutation
reinforces the importance of this region of capsid in
modulating HIV-1 sensitivity to MxB. Considering that
the A208 residue of capsid has a 35% prevalence rate in
the circulating HIV-1 strains (http://www.hiv.lanl.gov/
content/index), the G208A variant may serve a distinct
mechanism, in addition to the variants in the CypA-
binding loop, that HIV-1 employs to escape from MxB
restriction in vivo.
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